Minerva

Gliflozins and reducing cardiovascular events . . . and other stories

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2677 (Published 07 June 2017) Cite this as: BMJ 2017;357:j2677

Gliflozins and cardiovascular protection

Plenty of drugs lower blood glucose in people with type 2 diabetes, and produce millions in revenue for their manufacturers. But it came as a surprise even to the trialists when one drug, empagliflozin, produced a clear signal of benefit in reducing cardiovascular events as well as sugar (Circulation doi:10.1161/CIRCULATIONAHA.117.029190). Most trials of other drugs in the sodium-glucose co-transporter-2 inhibitor (SGLT-2i) class were not powered to show a similar effect, but an observational study based on registry data from more than 300 000 patients in Europe and the United States suggests a reduction in heart failure and cardiovascular death from all drugs in the SGLT-2i class.

Parent delivered CBT for anxious kids

Mental health services for …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe